{"url_path":"/sec/mcrb/proxy/2026-04-27/000114036126017092","section_key":"body","section_title":"DEFA14A body","topic":"sec","document":{"doc_type":"DEFA14A","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1609809/0001140361-26-017092-index.html","accession_number":"0001140361-26-017092","cik":"0001609809","ticker":"MCRB","issuer_name":"Seres Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1609809/0001140361-26-017092-index.html","primary_entity_key":"0001609809","primary_entity_name":"Seres Therapeutics, Inc."},"word_count":135,"has_tables":true,"body_markdown":"DEFA14A\n1\nef20071345_defa14a.htm\nDEFA14A\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n \n\n**SCHEDULE 14A**\n\n**PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE**\n\n**SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n \n\nFiled by the Registrant ☒\n\nFiled by a Party other than the Registrant ☐\n\nCheck the appropriate box:\n\n \n\n☐\n\nPreliminary Proxy Statement\n\n \n\n☐\n\n**Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**\n\n \n\n☐\n\nDefinitive Proxy Statement\n\n \n\n☒\n\nDefinitive Additional Material\n\n \n\n☐\n\nSoliciting Material under §240.14a-12\n\n**SERES THERAPEUTICS, INC.**\n\n**(Name of Registrant as Specified In Its Charter)**\n\n**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)**\n\nPayment of Filing Fee (Check the appropriate box):\n\n \n\n☒\n\nNo fee required.\n\n \n\n☐\n\nFee paid previously with preliminary materials.\n\n \n\n☐\n\nFee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11."}